Caden Biosciences Inc. is a life sciences tools and services company developing assays for G-Protein Coupled Receptors (GPCRs). GPCRs have been implicated in every major disease category, and thus are the most attractive and wellvalidated class of drug targets.

Since its inception, the company has established collaborations with leading pharmaceutical and biotech companies around its unique platform technology. Caden's approach measures each G protein pathway activation event separately, thus allowing the identification of compounds that are not only selective for the receptor, but are also selective for downstream signaling. There are a number of key benefits to using Caden’s technology, including:

• identify modulators for GPCRs activated by peptides/proteins
• identify isotype specific compounds of GPCRs (D1R vs D5R)
• identify allosteric modulators of GPCRs
• identify modulators for protease activated receptors (PAR1, PAR2, etc)
• identify inhibitors of constitutively activated receptors

Previously known as Cue Biotech, Inc., the company's recent name change and relocation to Madison, WI reflects its commitment to exclusively focus on its core business of developing assays and providing solutions to its pharmaceutical industry partners.